Abstract:Purpose: The dilemma of undertreatment and overtreatment of elderly breast cancer patients is common. This study aimed to investigate clinicopathological features, treatment modalities, and survival in women diagnosed with breast cancer at age 70 years or over, and to assist clinicians in developing individualized treatment plans by balancing the risks of breast cancer-specific death (BCSD) and other cause-specific death (OCSD). Methods: This retrospective study included 420 women who were diagnosed with pathologically confirmed invasive breast cancer at age 70 years or older from January 2008 to December 2015 at Peking University People's Hospital (PKUPH). We collected baseline health status, tumor characteristics, treatment choices, and outcomes and created nomograms for clinicians to estimate individualized BCSD and OCSD risk directly. Results: During a median follow-up of 71.5 months (range 2 to 144 months) in patients with stage I–III tumors, breast cancer specific survival (BCSS) was 92.4% (376/407) and overall survival (OS) was 78.1% (318/407). There were 89 deaths, and 65.2% (58/89) were non-breast cancer related. Upon multivariate analysis by Cox regression model, tumor size, positive lymph nodes, Ki-67, and surgery were independent predictors of BCSS, and comorbidities, positive lymph nodes, Ki-67, surgery, and endocrine therapy were independent predictors of OS. Propensity score weighted (PSW) was applied to analyze therapeutic efficacy, and there was BCSS and OS benefit with surgery (both p < 0.001), BCSS benefit with chemotherapy ( p = 0.029), BCSS and OS benefit with endocrine therapy ( p = 0.006 and 0.004), and neither BCSS nor OS benefit with radiotherapy (RT) ( p = 0.348 and 0.289). Competing-risk nomograms were developed to estimate cumulative mortality probabilities for BCSD and OCSD for individual patients according to clinicopathologic characteristics and treatments. The calibration curves displayed exceptionally, with C-indexes 0.714 for BCSD and 0.717 for OCSD. Conclusions: Older patients had greater risk of dying from non-breast cancer causes. Surgery, chemotherapy, and endocrine therapy were associated with improved survival. Competing risk nomograms allowed individual assessment of BCSD and OCSD, based on clinicopathological characteristics and treatment options, and can be used as a tool to help in choosing appropriate treatment strategies. This study was approved by the Peking University People's Hospital Research Ethics Board on September 4, 2018.

Hazard of Breast Cancer-Specific Mortality among Women with Estrogen Receptor-Positive Breast Cancer after Five Years from Diagnosis: Implication for Extended Endocrine Therapy

EFFECT OF ADJUVANT ENDOCRINE THERAPY ON ESTROGEN RECEPTOR-NEGATIVE, PROGESTERONE RECEPTOR-POSITIVE AND HER2 NEGATIVE BREAST CANCER PATIENTS

Breast Cancer-Specific Mortality Pattern and Its Changing Feature According to Estrogen Receptor Status in Two Time Periods

ER-positive Breast Cancer Patients with More Than Three Positive Nodes or Grade 3 Tumors Are at High Risk of Late Recurrence after 5-Year Adjuvant Endocrine Therapy

De‐escalation of five‐year adjuvant endocrine therapy in patients with estrogen receptor‐low positive (immunohistochemistry staining 1%‐10%) breast cancer: Propensity‐matched analysis from a prospectively maintained cohort

Risk of Second Primary Cancers among Long-Term Survivors of Breast Cancer

Identify High Risk Estrogen Receptor-Positive Breast Cancer Patients for Extended Endocrine Therapy.

Time-Varying Prognostic Impact of Hormone Receptors for Breast Cancer Patients

Abstract P2-14-04: Effect of Age at the Time of Diagnosis on Overall and Cancer-Specific Mortality in Breast Cancer: Analysis of SEER, 1990-2008

De-escalation of Five-Year Adjuvant Endocrine Therapy in Patients with ER-low Positive Breast Cancer: Propensity-matched Analysis from a Prospectively Maintained Cohort

Impact of extended endocrine therapy for patients with risk factors for late recurrence in estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after 5 years of endocrine therapy

Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor–Positive Breast Cancer

Prolonged endocrine therapy in the management of hormone receptor-positive early-stage breast cancer: What is the appropriate duration?

Evaluating and Balancing the Risk of Breast Cancer-Specific Death and Other Cause-Specific Death in Elderly Breast Cancer Patients

Impact of Adjuvant Chemotherapy on the Survival of Patients with Estrogen Receptor ≥50 ％, Human Epidermal Growth Factor Receptor-2 Negative, Lymph Node Negative Breast Cancer

Association of Hormone Receptor Status with Cardiovascular Disease Mortality in 399,209 Patients with Stage I to III Breast Cancer: A Population-Based Study

Long-Term Risk of Death From Heart Disease Among Breast Cancer Patients

Risk Factors for Recurrence after 5-Year Endocrine Therapy in Postoperative Breast Cancer Patients

Incidence and Survival Outcomes of Breast Cancer with Synchronous Hepatic Metastases: A Population-Based Study.

Effect of Radiotherapy on Survival of Women with Locally Excised Ductal Carcinoma in Situ of the Breast: a Surveillance, Epidemiology, and End Results Population-Based Analysis.

Risk of breast cancer recurrence remains for years after endocrine treatment ends, study finds